Neuronetics (STIM) director awarded 30,000 RSUs vesting by 2027
Rhea-AI Filing Summary
Cucuz Sasha reported acquisition or exercise transactions in this Form 4 filing.
Neuronetics, Inc. director Sasha Cucuz received an award of 30,000 restricted stock units (RSUs) of common stock. The RSUs vest on the earlier of May 28, 2027 or a Board-approved separation of service or change in control, in each case requiring continuous service until that date.
Each RSU represents a contingent right to receive one share of Neuronetics common stock. Following this grant, Cucuz directly holds 1,542,798 shares. Separate indirectly held shares are reported as held by Greybrook Health Inc. (516,084 shares) and Greybrook Realty Partners Inc. (2,042 shares), with beneficial ownership of these indirect holdings disclaimed except to the extent of his pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 30,000 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (3)
- F1. Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 28, 2027 or (b) the Reporting Person's Board-approved separation of service from the Issuer or change in control of the Issuer, in each case subject to continuous service of the Reporting Person through such date.
- F2. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- F3. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Key Figures
Key Terms
restricted stock unit ("RSU") financial
change in control financial
beneficial ownership financial
pecuniary interest financial
Section 16 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.